[go: up one dir, main page]

PE20040511A1 - Moduladores biciclicos de la funcion del receptor de androgeno - Google Patents

Moduladores biciclicos de la funcion del receptor de androgeno

Info

Publication number
PE20040511A1
PE20040511A1 PE2003000480A PE2003000480A PE20040511A1 PE 20040511 A1 PE20040511 A1 PE 20040511A1 PE 2003000480 A PE2003000480 A PE 2003000480A PE 2003000480 A PE2003000480 A PE 2003000480A PE 20040511 A1 PE20040511 A1 PE 20040511A1
Authority
PE
Peru
Prior art keywords
alkyl
alkenyl
hydroxy
modulators
bicycle
Prior art date
Application number
PE2003000480A
Other languages
English (en)
Inventor
Chongqing Sun
Lawrence Hamann
David Augeri
Jeffrey Robl
Tammy Wang
Alexandra Holubec
Ligaya Simpkins
Yan-Ting Huang
Yingzhi Bi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20040511A1 publication Critical patent/PE20040511A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE FORMULA I DONDE R1 ES H, ALQUILO, ALQUENILO, ARILALQUILO, ENTRE OTROS; R2 Y R2' SON H, ALQUILO, SR3, ENTRE OTROS; R3 ES H, ALQUILO, CHF2, CF3, ENTRE OTROS; R4 Y R4' ES H, ALQUILO, ALQUENILO, ENTRE OTROS; R5 Y R5' SON, H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R6 Y R6' SON H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; G ES ARILO, HETEROCICLO O HETEROARILO, ENTRE OTROS; W ES CR6R6', C(R6)OR3, C(R6)(NR4R4'), ENTRE OTROS; n ES UN NUMERO ENTERO DE 1 O 2. SON COMPUESTOS PREFERIDOS: ESTER METILICO DEL ACIDO (2S,3R)-3-HIDROXI-2-PIRROLIDINCARBOXILICO, (7R,7aS)-4-(7-HIDROXI-1,3 DIOXOTETRAHIDROPIRROLO[1,2-C]IMIDAZOL-2-IL)-5,6,7,8-TETRAHIDRONAFTALEN-1-CARBONITRILO Y (7R,7aS)-7-(7-HIDROXI-1,3-DIOXOTETRAHIDROPIRROLO[1,2-C]IMIDAZOL-2-IL)-INDAN-4-CARBONITRILO, ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR ANDROGENO UTILES EN EL TRATAMIENTO DE CONDICIONES ASOCIADAS AL RECEPTOR DE LA HORMONA NUCLEAR TALES COMO SARCOPENIA, SINDROME DE FATIGA CRONICA (CFS) Y EFECTOS COLATERALES CATABOLICOS DE LOS GLUCOCORTICOIDES
PE2003000480A 2002-05-17 2003-05-19 Moduladores biciclicos de la funcion del receptor de androgeno PE20040511A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38161602P 2002-05-17 2002-05-17
US40671102P 2002-08-29 2002-08-29

Publications (1)

Publication Number Publication Date
PE20040511A1 true PE20040511A1 (es) 2004-08-25

Family

ID=29553541

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000480A PE20040511A1 (es) 2002-05-17 2003-05-19 Moduladores biciclicos de la funcion del receptor de androgeno

Country Status (11)

Country Link
US (1) US20040019063A1 (es)
EP (1) EP1506178A4 (es)
JP (1) JP4637572B2 (es)
AR (1) AR040030A1 (es)
AU (1) AU2003234609A1 (es)
IS (1) IS7527A (es)
MY (1) MY139579A (es)
PE (1) PE20040511A1 (es)
PL (1) PL373394A1 (es)
TW (1) TW200407324A (es)
WO (1) WO2003096980A2 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
DE60228330D1 (de) * 2001-12-19 2008-09-25 Bristol Myers Squibb Co Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1546162B1 (en) 2002-09-20 2011-06-22 Promega Corporation Luminescence-based methods and probes for measuring cytochrome p450 activity
AU2003302084A1 (en) * 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
ES2321088T3 (es) 2003-08-08 2009-06-02 Amgen Fremont Inc. Anticuerpos dirigidos frente a la hormona paratiroidea (pth) y usos de los mismos.
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
AU2004305075A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
AU2005247405A1 (en) * 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
MX2007008334A (es) 2005-01-10 2007-09-11 Acadia Pharm Inc Derivados aminofenilo como moduladores de receptor de androgeno selectivos.
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP1935986B1 (en) 2005-05-31 2014-04-16 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
EP2277872B1 (en) 2005-05-31 2016-03-23 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
PT1928886E (pt) 2005-09-09 2011-07-14 Glaxosmithkline Llc Derivados de piridina e sua utilização para o tratamento de distúrbios psicóticos
AU2007215004B2 (en) * 2006-02-10 2012-03-01 Janssen Pharmaceutica N.V. Bicyclic imidazole or thiadiazole heterocycles useful as selective androgen receptor modulators
US7655683B2 (en) 2006-02-10 2010-02-02 Janssen Pharmaceutica Nv Imidazolopyrazole derivatives useful as selective androgen receptor modulators
DK2656842T3 (en) * 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
AU2012241184B2 (en) * 2006-03-27 2016-01-07 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2013205325B2 (en) * 2006-03-27 2016-03-24 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
GB0610765D0 (en) * 2006-05-31 2006-07-12 Proskelia Sas Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
EP2220050A2 (en) 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8124636B2 (en) * 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US20130053448A1 (en) 2010-05-12 2013-02-28 Louis O'Dea Therapeutic Regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
MX2014001086A (es) 2011-07-27 2014-02-27 Novartis Ag Derivados de pirazolina y su uso como moduladores selectivos de los receptores de androgenos.
JP2015006993A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 イミダゾロン誘導体
CN104169258B (zh) * 2011-12-22 2017-03-01 默克专利有限公司 用作激酶活性调节剂的新颖的杂环羧酰胺
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP3099683B1 (en) 2014-01-29 2020-08-05 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
JP6863832B2 (ja) * 2016-07-21 2021-04-21 日清ファルマ株式会社 筋萎縮抑制用組成物
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
CN118475567A (zh) 2021-08-11 2024-08-09 西藏海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) * 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
NL6704169A (es) * 1966-04-06 1967-10-09
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4036979A (en) * 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
CA1076114A (en) * 1975-02-10 1980-04-22 Mitsubishi Chemical Industries Limited 1,5-alkylene-3-aryl hydantoin derivatives
JPS5195134A (es) * 1975-02-10 1976-08-20
JPS5933593B2 (ja) * 1976-01-01 1984-08-16 三菱化学株式会社 ヒダントイン又はチオヒダントインの誘導体
JPS55153763A (en) * 1979-05-21 1980-11-29 Kyowa Hakko Kogyo Co Ltd Modifier for citrus fruits
JPS57175189A (en) * 1981-04-21 1982-10-28 Kyowa Hakko Kogyo Co Ltd Benzothiazole derivative and its preparation
US4859684A (en) * 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
DE3809390A1 (de) * 1988-03-16 1989-09-28 Schering Ag Perhydro-imidazopyridine und -pyrroloimidazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel
DE3827221A1 (de) * 1988-08-11 1990-02-15 Bayer Ag Substituierte n-phenyl-stickstoff- bzw. stickstoff-schwefel-heterocyclen, verfahren sowie entsprechende heterocyclische phenolderivate, phenyliso(thio)cyanate und -carbamate als zwischenprodukte zu ihrer herstellung, ihre verwendung in herbiziden und pflanzenwuchsregulierenden mitteln
US5179080A (en) * 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
HUT62296A (en) * 1990-12-18 1993-04-28 Sandoz Ag Herbicidal composition comprising hydantoin derivative as active ingredient and process for producing the active ingredient
KR100335021B1 (ko) * 1992-09-10 2002-09-27 데구사 아게 제초제로서의비사이클릭이미드
IL107719A0 (en) * 1992-12-21 1994-02-27 Du Pont Imidazolones their manufacture and their use as herbicides
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5693647A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6310095B1 (en) * 1995-11-06 2001-10-30 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
CA2376957A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
WO2001007052A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
PT1307455E (pt) * 1999-10-20 2005-06-30 Tanabe Seiyaku Co Inibidores de adesao celular mediada por (alfa)l (beta)2
ATE319712T1 (de) * 1999-12-21 2006-03-15 Mgi Gp Inc Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
WO2003011824A1 (en) * 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200303200A (en) * 2002-02-07 2003-09-01 Tanabe Seiyaku Co Inhibitors of α L β 2 integrin mediated cell adhesion

Also Published As

Publication number Publication date
TW200407324A (en) 2004-05-16
MY139579A (en) 2009-10-30
AR040030A1 (es) 2005-03-09
EP1506178A4 (en) 2006-05-24
AU2003234609A8 (en) 2003-12-02
IS7527A (is) 2004-11-12
JP2005531555A (ja) 2005-10-20
WO2003096980A3 (en) 2004-10-21
WO2003096980A2 (en) 2003-11-27
US20040019063A1 (en) 2004-01-29
JP4637572B2 (ja) 2011-02-23
AU2003234609A1 (en) 2003-12-02
EP1506178A2 (en) 2005-02-16
PL373394A1 (en) 2005-08-22

Similar Documents

Publication Publication Date Title
PE20040511A1 (es) Moduladores biciclicos de la funcion del receptor de androgeno
AR033306A1 (es) Compuestos
PE20070798A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20090957A1 (es) Moduladores de gamma secretasa
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
PE20050123A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas y composiciones farmaceuticas que los incluyen
PE20070018A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20142216A1 (es) Inhibidores de indazol de la ruta de senalizacion de wnt y usos terapeuticos de los mismos
RU2000115576A (ru) 2-гетероарилалкенилпроизводные циклопентангептан(ен)овой кислоты
AR073688A1 (es) Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.
ZA200300828B (en) New aporphine esters and their use in therapy.
KR950700265A (ko) 고지혈증 치료에 유용한 벤조티아제핀 화합물(hypolipidaemic ben zothiazepine compounds)
AR035589A1 (es) Esteres de acido difenilmetilcarboxilico con efecto anticolinergico, un procedimiento para su preparacion, el uso de los mismos para la preparacion de un medicamento y los preparados farmaceuticos que los contienen
AR029417A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
RU2011116160A (ru) Производные пиридина, замещенные гетероциклическим кольцом и y-глутамиламиногруппой и содержащие их противогрибковые средства
MY113463A (en) Novel heterocyclic compounds
PE20071093A1 (es) COMPUESTOS HETEROCICLICOS BICICLICOS COMO MODULADORES DEL RECEPTOR CRTh2
DE50304030D1 (de) Verfahren zur Herstellung von 5-Nitrobenzofuranen
RU95114449A (ru) Производные 4-арил- или гетероарил-6-амино-никотиновой кислоты, смесь их изомеров или отдельные изомеры, а также фармацевтическая композиция с модулирующим калиевые канальцы действием
PE20010299A1 (es) DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5
PE20110206A1 (es) Derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
PE20080143A1 (es) Compuestos 2-oxo-3-fenil-(1,4-diazaespiro[4.5]dec-3-en-1-il)acetamida sustituidos como inhibidores del transportador de glicina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed